Hamilton C A
Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK.
Pharmacol Ther. 1997;74(1):55-72. doi: 10.1016/s0163-7258(96)00202-1.
Oxidation of low-density lipoprotein (LDL) may be implicated in the development of atherosclerotic disease. Oxidised LDL is taken up more readily by monocyte-derived macrophages than LDL. Antibodies to oxidised LDL are found in atherosclerotic lesions, Increased risk of ischaemic heart disease is associated with a preponderance of small dense LDL particles, which are more susceptible to oxidation. Proatherogenic alterations in cell biochemistry and signalling pathways occur in the presence of LDL and more markedly oxidised LDL. In vitro antioxidants inhibit changes in cell biochemistry, while in vivo, they have been shown to attenuate or reverse development of atherosclerosis.
低密度脂蛋白(LDL)的氧化可能与动脉粥样硬化疾病的发展有关。与LDL相比,单核细胞衍生的巨噬细胞更容易摄取氧化型LDL。在动脉粥样硬化病变中可发现针对氧化型LDL的抗体。缺血性心脏病风险增加与小而密的LDL颗粒占优势有关,这些颗粒更容易被氧化。在LDL尤其是氧化型LDL存在的情况下,细胞生物化学和信号通路会发生促动脉粥样硬化改变。体外抗氧化剂可抑制细胞生物化学变化,而在体内,它们已被证明可减轻或逆转动脉粥样硬化的发展。